Tags Archive Navigation
icon
-
Media ReleaseNovartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
-
Media ReleaseNovartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
-
Media ReleaseNovartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Media ReleaseNovartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
-
Media ReleaseNovartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition
-
Media ReleaseNovartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
-
Media ReleaseNovartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
-
Media ReleaseNovartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
-
Media ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis